Patent Assignment
Reel/Frame 066662/0210
Release of Security Interest
Recorded: 2024-01-04
Pages: 12
Assignor
U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Executed: 2024-01-02
Assignee
INTERCEPT PHARMACEUTICALS, INC.
305 MADISON AVENUE, MORRISTOWN, NEW JERSEY, 07960
Covered Properties
(92)
Steroid Agonist for Fxr
Treatment of fibrosis using FXR ligands
Steroids as Agonists for Fxr
Bile Acid Derivatives as Fxr Ligands for the Prevention or Treatment of Fxr-Mediated Diseases or Conditions
Process for Preparing 3A(Beta)-7A(Beta)-Dihydroxy-6A(Beta)-Alkyl-5BETA-Cholanic Acid
Bile Acid Derivatives as Fxr Ligands for the Prevention or Treatment of Fxr-Mediated Diseases or Conditions
23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof
Steroids as Agonists for Fxr
TGR5 Modulators and Methods of Use Therof
TGR5 Modulators And Methods Of Use Thereof
Bile Acid Derivatives As FXR Ligands For The Prevention Or Treatment Of FXR-Mediated Diseases Or Conditions
TGR5 Modulators and Methods of Use Thereof
Steroids as Agonists for Fxr
TGR5 Modulators and Methods of Use Thereof
Steroids as Agonists for Fxr
TGR5 Modulators and Methods of Use Thereof
TGR5 Modulators and Methods of Use Thereof
Preparation and Uses of Obeticholic Acid
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
Farnesoid X receptor modulators
Process for Preparing Bile Acid Derivatives
TGR5 Modulators and Methods of Use Thereof
Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
Preparation and Uses of Obeticholic Acid
Preparation and Uses of Obeticholic Acid
Preparation and Uses of Obeticholic Acid
Preparation and Uses of Obeticholic Acid
Steroids as Agonists for Fxr
Compositions of Obeticholic Acid and Methods of Use
Farnesoid X Receptor Modulators
Treatment of Fibrosis Using Fxr Ligands
3-Desoxy Derivative and Pharmaceutical Compositions Thereof
Methods of Treating Cancer
Preparation and Uses of Obeticholic Acid
Pharmaceutical Compositions for Combination Therapy
Fxr Agonist Compositions for Combination Therapy
Steroids as Agonists for Fxr
Process for Preparing Bile Acid Derivatives
Methods of Treating Cancer
Application:
15/711,205 →
Publication:
US 2018/0256600
TGR5 Modulators and Methods of Use Thereof
Methods for Preparation of Bile Acids and Derivatives Thereof
Methods for Preparation of Bile Acids and Derivatives Thereof
Methods of Promoting Hepatic Regeneration
Methods and Intermediates for the Preparation Bile Acid Derivatives
Methods for the Preparation of Obeticholic Acid and Derivatives Thereof
Methods and Intermediates for the Preparation of Bile Acid Derivatives
Compositions of Obeticholic Acid and Methods of Use
Medicine Obtained by Combining FXR Agonist and ARB
Oral Preparation of Obeticholic Acid
Film-Coated Tablet Having High Chemical Stability of Active Ingredient
Methods for the Preparation of Obeticholic Acid and Derivatives Thereof
Farnesoid X Receptor Modulators
Treatment of Fibrosis Using Fxr Ligands
Compositions of Obeticholic Acid and Methods of Use
Crystalline Forms of a Bile Acid Derivative
Application:
16/337,982 →
Publication:
US 2020/0024299
Steroids As Agonists For FXR
Patent:
48,286 →
Application:
16/448,503 →
Pharmaceutical Compositions of a Bile Acid Derivative and Microbiome and Uses Thereof
Application:
16/486,873 →
Publication:
US 2020/0164005
Crystalline Forms of Obeticholic Acid
Application:
16/491,798 →
Publication:
US 2021/0139528
Compositions of Obeticholic Acid and Methods of Use
Application:
16/596,741 →
Publication:
US 2020/0046736
Isotopically Labeled Bile Acid Derivatives
Farnesoid X Receptor Modulators
Compositions of Obeticholic Acid and Methods of Use
Methods of Diagnosis and Treatment of Liver Diseases Using Obeticholic Acid
Application:
16/831,365 →
Publication:
US 2020/0316092
Treatment of Fibrosis Using Fxr Ligands
Application:
16/922,978 →
TGR5 Modulators and Methods of Use Thereof
3-Desoxy Derivative and Pharmaceutical Compositions Thereof
TGR5 Modulators and Methods of Use Thereof
Application:
17/092,612 →
Publication:
US 2021/0269473
Preparation and Uses of Obeticholic Acid
Application:
17/142,870 →
Publication:
US 2021/0395293
Treatment of Fibrosis Using Fxr Ligands
Application:
17/211,033 →
Publication:
US 2021/0346400
Farnesoid X Receptor Modulators
Application:
17/228,819 →
Publication:
US 2021/0228599
Farnesoid X Receptor Modulators
Methods and Intermediates for the Preparation of Bile Acid Derivatives
Application:
17/342,057 →
Publication:
US 2022/0127302
Methods of Using Obeticholic Acid
Application:
17/384,555 →
Publication:
US 2022/0184099
Treatment and Prevention of Intestinal Inflammatory Diseases with a Bile Acid Derivative
Application:
17/428,029 →
Publication:
US 2022/0096495
Compositions of Obeticholic Acid and Methods of Use
Application:
17/542,923 →
Publication:
US 2022/0133745
Pharmaceutical Compositions Comprising a Fxr Agonist and a Fibrate for Use in the Treatment of Cholestatic Liver Disease
Application:
17/615,186 →
Publication:
US 2022/0226350
Pharmaceutical Compositions for Combination Therapy
Pharmaceutical Compositions for Combination Therapy
Application:
17/700,392 →
Publication:
US 2022/0280534
TGR5 Modulators and Methods of Use Thereof
Isotopically Labeled Bile Acid Derivatives
Application:
17/939,326 →
Publication:
US 2023/0057232
Preparation and Uses of Obeticholic Acid
Application:
18/188,341 →
Publication:
US 2023/0340010
Farnesoid X Receptor Modulators
Application:
18/295,091 →
Publication:
US 2023/0233581
Methods of Treating Coronaviral Infection with Obeticholic Acid
Application:
63/088,571 →
Methods and Intermediates for the Preparation of Bile Acid Derivatives
Application:
63/222,706 →
Combination Therapy
Application:
63/304,394 →
Uses of Farnesoid X Receptor Agonists
Application:
63/333,287 →
Methods for Ameliorating Cognitive Impairement Using Bile Acid Derivatives
Application:
63/358,088 →
Uses of Farnesoid X Receptor Agonists
Application:
63/381,752 →
Uses of Farnesoid X Receptor Agonists
Application:
63/381,754 →
Crystalline Forms of a Farnesoid X Receptor Agonist
Application:
63/383,479 →
Methods and Intermediates for the Preparation of Bile Acid Derivatives
Application:
63/442,534 →
Uses of Farnesoid X Receptor Agonists
Application:
63/497,602 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 8, 2005
From: FIORUCCI, STEFANO; PELLICCIARI, ROBERTO; PRUZANSKI, MARK
To: INTERCEPT PHARMACEUTICALS INC.
Reel/Frame 017107/0589 →
Assignment of Assignor's Interest
Jul 3, 2007
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 019592/0153 →
Assignment of Assignor's Interest
Nov 20, 2007
From: FERRARI, MASSIMO; PELLICCIARI, ROBERTO
To: ERREGIERRE S.P.A.
Reel/Frame 020136/0481 →
Assignment of Assignor's Interest
Oct 9, 2009
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 023353/0320 →
Assignment of Assignor's Interest
Oct 20, 2009
From: ERREGIERRE S.P.A.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 023397/0038 →
Assignment of Assignor's Interest
Feb 4, 2010
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 023899/0797 →
Assignment of Assignor's Interest
Mar 29, 2010
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 024153/0831 →
Assignment of Assignor's Interest
May 10, 2010
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 024357/0612 →
Sponsored Research Agreement
Sep 30, 2010
From: FIORUCCI, STEFANO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025070/0367 →
Sponsored Research Agreement
Sep 30, 2010
From: FIORUCCI, STEFANO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025086/0523 →
Assignment of Assignor's Interest
Sep 30, 2010
From: PELLICCIARI, ROBERTO; PRUZANSKI, MARK
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025072/0095 →
Assignment of Assignor's Interest
Sep 30, 2010
From: PELLICCIARI, ROBERTO; PRUZANSKI, MARK
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025071/0006 →
Change of Address of Assignee
Oct 13, 2010
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025130/0799 →
Change of Address of Assignee
Oct 13, 2010
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025130/0816 →
Assignment of Assignor's Interest
Oct 27, 2010
From: ERREGIERRE SPA
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025202/0921 →
Amended and Restated Sponsored Research Agreement
Jan 14, 2011
From: FIORUCCI, STEFANO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025635/0952 →
Change of Address of Assignee
Jan 21, 2011
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025672/0866 →
Change of Address of Assignee
Jan 31, 2011
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 025721/0419 →
Assignment of Assignor's Interest
Mar 24, 2011
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 026011/0898 →
Assignment of Assignor's Interest
Jul 18, 2011
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 026606/0691 →
Assignment of Assignor's Interest
Nov 7, 2011
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 027184/0696 →
Assignment of Assignor's Interest
Jan 4, 2013
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 029567/0594 →
Assignment of Assignor's Interest
Mar 11, 2013
From: PELLICCIARI, ROBERTO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 029962/0282 →
Amended and Restated Sponsored Research Agreement
Jun 4, 2013
From: FIORUCCI, STEFANO
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 030555/0093 →
Change of Name
Jun 4, 2013
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 030555/0115 →